<DOC>
	<DOCNO>NCT02349685</DOCNO>
	<brief_summary>As increase antibiotic resistance , effectiveness traditional Helicobacter pylorus ( H. pylorus ) therapy decline coincidently . In study , investigator evaluate efficacy H. pylori eradication personalize therapy H. pylorus infection base result antibiotic resistance use H. pylori culture minimal inhibitory concentration ( MIC ) traditional 2nd rescue regimen , investigator analyze prevalence antibiotic resistance 1st eradication H. pylorus tailor therapy group .</brief_summary>
	<brief_title>The Efficacy Tailored Therapy Based Antimicrobial Susceptibility 2nd Eradication H. Pylori</brief_title>
	<detailed_description>The patient show evidence persistent H. pylori infection 1st eradication enrol study . After give informed consent method efficacy ( ITT PP analysis ) traditional 2nd rescue therapy tailor therapy H. pylorus infection base culture MIC , patient classify three regimen group patient 's agreement underwent 2nd eradication [ 14 day bismuth-based quadruple therapy ( Proton pump inhibitor ( PPI ) regular dose b.i.d. , tripotassium dicitrate bismuthate 300 mg q.i.d . ( three tablet 30 min meal one tablet 2 hour dinner ) , metronidazole 500 mg t.i.d. , tetracycline 500 mg q.i.d . ) , 14 day moxifloxacin-containing triple therapy ( PPI regular dose b.i.d. , moxifloxacin 400 mg q.d. , amoxicillin 1g b.i.d . ) , tailor therapy base H. pylori culture MIC ( select 2nd rescue regimen 14 day bismuth-based quadruple therapy 14 day moxifloxacin-containing triple therapy accord antibiotic susceptibility ) ] .This study analyze success eradication enrol participant retrospectively , however patient enrol prospectively base previous study antimicrobial susceptibility test H. pylorus Korea .</detailed_description>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>The patient prove failure 1st eradication H. pylori Proton pump inhibitor base triple therapy ( PPI bid + amoxacillin 1g b.i.d + Clarithromycin 500 mg b.i.d ) sequential therapy ( initial 5day therapy combination PPI b.i.d amoxicillin 1g b.i.d , follow 5 day PPI b.i.d. , clarithromycin 500mg b.i.d. , metronidazole 500mg t.i.d ) follow three method 1. positive rapid urease test ( CLOtest ) 2. histologic evidence H. pylorus modify Giemsa stain 3. positive 13CUrea breath test Male female Korean Adult ( Aged â‰¥ 18 year ) Patients receive two eradication therapy H. pylorus infection H. pylori eradication failure poor compliance administration antibiotic consumption bismuth salt within 4 week administration proton pump inhibitor ( PPI ) within 2 week Advanced gastric cancer malignancy Abnormal liver function liver cirrhosis Abnormal renal function chronic kidney disease Other severe concurrent diseases Previous allergic reaction study drug Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>Personalized therapy</keyword>
	<keyword>antimicrobial susceptibility</keyword>
	<keyword>rescue therapy</keyword>
	<keyword>culture</keyword>
</DOC>